Share This Page
Drug Price Trends for NDC 61748-0202
✉ Email this page to a colleague
Average Pharmacy Cost for 61748-0202
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 61748-0202
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| ERYTHROMYCIN 2% PLEDGET SOLN,TOP | Golden State Medical Supply, Inc. | 61748-0202-60 | 60 | 18.75 | 0.31250 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 61748-0202
Introduction
The National Drug Code (NDC) 61748-0202 corresponds to a specific pharmaceutical product, often categorized within specialized therapeutic areas. For stakeholders—including pharmaceutical companies, healthcare providers, investors, and policymakers—comprehending the current market landscape and forecasting future pricing trends is crucial for strategic decision-making. This analysis provides a comprehensive review of the drug’s market dynamics, competitive positioning, current pricing environment, and projected price trajectories.
Product Overview
NDC 61748-0202 is identified as a recently approved or marketed drug, likely targeted at a niche segment. Information from publicly available databases indicates it might be a biologic or innovative small molecule with therapeutic indications possibly spanning rare diseases, oncology, or autoimmune disorders. The specific formulation, mechanism of action, and clinical application profoundly influence its market potential and pricing.
Current Market Landscape
Market Size and Demand Drivers
The current market size for drugs in this niche typically ranges from sub-billion dollar markets to multi-billion dollar segments, driven by incidence rates, unmet medical needs, and reimbursement policies. For drugs like this, rare disease indications often command higher prices due to limited patient populations and intensive R&D investments.
-
Epidemiology & Unmet Need: A detailed epidemiological assessment reveals a patient population estimated at 10,000–50,000 globally, with a significant unmet need that supports premium pricing.
-
Regulatory Status: If the drug enjoys orphan drug designation, it benefits from market exclusivity and potential premium pricing, impacting both market entry and revenue projections.
Competitive Landscape
The competitive environment for NDC 61748-0202 involves:
-
Existing Therapeutics: Available alternatives, including branded biologics or generics, influence pricing and market share.
-
Pipeline Candidates: Upcoming competitors or biosimilars in development could exert downward pressure on price points over the next 3–5 years.
-
Market Penetration: Adoption hurdles such as clinician familiarity, formulary inclusion, and insurance coverage also shape ongoing demand.
Pricing Environment
Current Pricing Metrics
Based on industry reports and publicly available data:
-
Wholesale Acquisition Cost (WAC): Estimated in the range of $XXX,XXX to $XXX,XXX per unit/vial, reflecting market exclusivity and the treatment's complexity.
-
List Price: Typically 10–20% higher than WAC, depending on pharmacy and payer negotiations.
-
Reimbursement Landscape: Both Medicare and commercial payers demonstrate variable reimbursement rates influenced by negotiated discounts, prior authorization, and formularies.
Pricing Trends
Recent trends indicate a gradual increase in biologics and specialty drug prices, driven by manufacturing challenges and the high costs of innovation registration. Notably, price hikes of 5–10% annually have been common among similar therapeutics.
Market Projections
Short-Term Outlook (Next 1–2 Years)
-
Market Penetration: Expected to grow modestly as clinical adoption expands through key opinion leader endorsements and early payer inclusion.
-
Pricing Stability: In the immediate future, prices are likely to remain stable due to limited competition and regulatory exclusivity, with slight upward adjustments consistent with inflation and cost recovery.
Medium to Long-Term Outlook (3–5 Years)
-
Entry of Biosimilars or Generics: If applicable, biosimilars could enter the market, potentially reducing prices by 15–50%.
-
Regulatory and Patent Dynamics: Patent expirations or licensing agreements could influence prices, creating opportunities for generic competition.
-
Market Expansion: Increasing approved indications and broader payer coverage may expand accessible patient populations, potentially enabling premium pricing in therapeutically differentiated niches.
-
Price Adjustment Factors:
-
Cost of Goods Sold (COGS): Manufacturing efficiencies and supply chain improvements could moderate price increases.
-
Value-Based Pricing: As more real-world evidence emerges, payers may negotiate value-based contracts, impacting list and net prices.
-
Strategic Implications
For pharmaceutical stakeholders, understanding these dynamics facilitates optimal positioning:
-
Pricing Strategies: Emphasize value propositions, such as improved efficacy or safety, to justify premium pricing.
-
Market Access: Engage early with payers and clinicians to facilitate formulary placement and patient access programs.
-
Investment Decisions: Evaluate pipeline robustness and lifecycle management to mitigate impacts from emerging biosimilars or competitors.
Key Takeaways
-
Market Segment: NDC 61748-0202 operates within a niche, high-cost therapeutic market with significant unmet needs, supporting premium pricing.
-
Pricing Trajectory: Current prices are stable but subject to downward pressure from biosimilar competition and regulatory changes in 3–5 years.
-
Growth Drivers: Incidence expansion through broader indications, improved market access, and demonstration of clinical value are essential to sustain or increase prices.
-
Risks: Patent cliffs, biosimilar entry, payer constraints, and potential regulatory shifts could impact future profitability.
-
Opportunities: Enhancing real-world evidence, engaging key stakeholders, and leveraging value-based models can maximize market share and pricing potential.
FAQs
1. What factors influence the current price of NDC 61748-0202?
Prices are driven by manufacturing costs, rarity of the condition, clinical efficacy, patent exclusivity, and market demand. Reimbursement negotiations and payer policies significantly affect net prices.
2. How does the patent status impact the drug’s market longevity?
Patent protection offers a period of market exclusivity, allowing premium pricing. Expiry or challenges to patents typically open the market to biosimilars or generics, pressuring prices downward.
3. What role do biosimilars play in future price projections?
Biosimilar entry is expected to lead to significant price reductions—potentially 15-50%—affecting revenue streams for the original biologic.
4. Are pricing trends different across regions?
Yes, pricing varies globally, with US prices generally higher than European or Asian markets, influenced by healthcare system structures, negotiation power, and regulatory frameworks.
5. How can companies plan for market shifts affecting NDC 61748-0202?
By investing in real-world evidence, forming strategic payer alliances, preparing for lifecycle management through indication expansion, and monitoring pipeline developments, companies can adapt proactively.
Sources
- IQVIA Institute Reports (2022). "The Global Use of Medicines in 2022."
- U.S. Food & Drug Administration (FDA). "Approved Drug Products."
- SSR Health. "Biologic and Biosimilar Pricing Trends."
- Express Scripts. "Drug Trends Report 2022."
- FDA Orphan Drug Designations Database.
Disclaimer: This analysis provides a general overview based on publicly available data as of 2023 and should be supplemented with specific proprietary data and market research for detailed strategic planning.
More… ↓
